REG - LungLife AI, INC - Health economics publication

LungLife AIAnnouncement

07/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230307:nRSG0731Sa&default-theme=true

RNS Number : 0731S  LungLife AI, INC  07 March 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Nodule evaluation using LungLB® projected to be cost-effective in US
healthcare system

 

Data strongly support payor coverage of indeterminate lung nodule evaluation
using LungLB® in peer-reviewed publication in the Journal of Medical
Economics.

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces that further to its announcement on 27 February 2023, the
final version of the health economics publication is now available. There have
been no changes to the results or conclusions, which show LungLB® is
projected to be a cost-effective solution for US insurers covering individuals
with indeterminate lung nodules.

 

The publication can now be accessed here: Journal of Medical Economics Vol 26
(https://www.tandfonline.com/doi/full/10.1080/13696998.2023.2182493)

 

 

For further information please contact:

 

 LungLife AI, Inc.                                       www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                        Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)          Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Walbrook PR Limited                                      Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                         (mailto:LungLifeAI@walbrookpr.com)
 Stephanie Cuthbert / Alice Woodings / Phillip Marriage  Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
Our Vision is to invert the 20:80 ratio such that in years to come at least
80% of lung cancer is detected early.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBQLLBXXLFBBF